Eton Pharmaceuticals, Inc. · NASDAQ:ETON
Brynjelsen Sean sold 100,000 Eton Pharmaceuticals, Inc. shares (Form 4)
Traded Aug 19 to Aug 20, 2026 · Filed Aug 20, 2026
From Aug 19 to Aug 20, 2026, Brynjelsen Sean (Director, President & CEO) sold 100,000 Eton Pharmaceuticals, Inc. shares at an average US$60.88 for US$6.09M, leaving 961,194 shares. Filed Aug 20, 2026 (Form 4).
- Sold
- 100,000 shares
- Price
- US$60.88 average (US$60.17 to US$62.65)
- Value
- US$6.09M
- Holding after
- 961,194 shares
- Trading plan
- No
- Role
- Director, President & CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Common Stock | Sale | 8,978 | US$62.65 | 1,052,216 | Direct |
| Aug 20, 2026 | Common Stock | Sale | 47,307 | US$60.17 | 1,004,909 | Direct |
| Aug 20, 2026 | Common Stock | Sale | 36,373 | US$61.11 | 968,536 | Direct |
| Aug 20, 2026 | Common Stock | Sale | 7,342 | US$62.12 | 961,194 | Direct |
Source
Related
- Eton Pharmaceuticals, Inc.
- Brynjelsen Sean
- Eton Pharmaceuticals, Inc. shareholders
- Form 4 · Brynjelsen Sean · Jul 14, 2026
- Form 4 · Brynjelsen Sean · May 29, 2026
- Form 4 · Krempa David · Oct 6, 2026
- Form 4/A · Maier Paul V · Aug 31, 2026
- Form 4 · Krempa David · Aug 24, 2026
- Schedule 13G/A · BlackRock, Inc. · Jul 28, 2026
- Form 4/A · Opaleye Management Inc. · Jul 17, 2026